A0789412
Alfuzosin hydrochloride , ≥98% , 81403-68-1
Synonym(s):
Alfuzosin hydrochloride;N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide hydrochloride;Uroxatral hydrochloride
CAS NO.：81403-68-1
Empirical Formula: C19H28ClN5O4
Molecular Weight: 425.91
MDL number: MFCD00879135
EINECS: 620-512-3
| Pack Size | Price | Stock | Quantity |
| 25MG | RMB100.00 | In Stock |
|
| 50MG | RMB159.20 | In Stock |
|
| 100mg | RMB272.00 | In Stock |
|
| 250MG | RMB530.40 | In Stock |
|
| 1G | RMB1185.60 | In Stock |
|
| 5g | RMB2865.60 | In Stock |
|
| others | Enquire |
Update time: 2022-07-08
PRODUCT Properties
| Melting point: | 225°C |
| storage temp. | 2-8°C |
| solubility | DMSO: >10mg/mL |
| pka | 8.13(at 25℃) |
| form | solid |
| color | White to Off-White |
| Merck | 14,238 |
Description and Uses
Alfuzosin (SL-77499) (I), a quinazoline derivative which is a uroselective alpha-1 adrenoreceptor antagonist, has been developed and launched worldwide by Sanofi-Synthelabo, for the treatment of benign prostate hyperplasia (BPH). In November 2003, alfuzosin (I) was launched as an extended release formulation in the US as Uroxatral utilizing Skyepharma’s oral controlled release technology.
Antihypertensor;Alpha 1- adrenergic antagonist
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302 |
| Precautionary statements | P264-P270-P301+P312-P330-P501 |
| Hazard Codes | Xn |
| Risk Statements | 22 |
| WGK Germany | 3 |
| RTECS | LT9965475 |
| HS Code | 2934990002 |
